Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab
Giant cell carcinoma, a rare variant of nonsmall cell lung carcinoma (NSCLC), is characterized by aggressive progression and poor response to conventional chemotherapy. This report is the first to describe a patient with NSCLC and giant cell features who was successfully treated with pembrolizumab,...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2018/5863015 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553526652305408 |
|---|---|
| author | Shingo Nakayama Mamoru Sasaki Shojiroh Morinaga Naoto Minematsu |
| author_facet | Shingo Nakayama Mamoru Sasaki Shojiroh Morinaga Naoto Minematsu |
| author_sort | Shingo Nakayama |
| collection | DOAJ |
| description | Giant cell carcinoma, a rare variant of nonsmall cell lung carcinoma (NSCLC), is characterized by aggressive progression and poor response to conventional chemotherapy. This report is the first to describe a patient with NSCLC and giant cell features who was successfully treated with pembrolizumab, an antibody targeting programmed death-1 (PD-1). A 69-year-old woman was diagnosed with NSCLC with multiple brain metastases. Histological evaluation of lung biopsy specimens revealed proliferation of pleomorphic giant tumor cells with poor cohesiveness, findings consistent with giant cell carcinoma. Immunostaining showed that a high proportion of the tumor cells were positive for expression of programmed death-ligand 1 (PD-L1). The patient received stereotactic radiotherapy for the brain metastases, followed by administration of pembrolizumab. Treatment with pembrolizumab resulted in the rapid regression of the primary lung nodule, with the progression-free period maintained for at least four treatment cycles. Immunotherapy targeting PD-1/PD-L1 may be an option for patients with PD-L1-positive NSCLC with giant cell features. |
| format | Article |
| id | doaj-art-24a27a54f0e44b0c8ae7b402aecc7c98 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-24a27a54f0e44b0c8ae7b402aecc7c982025-02-03T05:53:48ZengWileyCase Reports in Oncological Medicine2090-67062090-67142018-01-01201810.1155/2018/58630155863015Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with PembrolizumabShingo Nakayama0Mamoru Sasaki1Shojiroh Morinaga2Naoto Minematsu3Department of Medicine, Hino Municipal Hospital, 4-3-1 Tamadaira, Hino-shi, Tokyo 191-0062, JapanDepartment of Medicine, Hino Municipal Hospital, 4-3-1 Tamadaira, Hino-shi, Tokyo 191-0062, JapanDepartment of Diagnostic Pathology, Hino Municipal Hospital, 4-3-1 Tamadaira, Hino-shi, Tokyo 191-0062, JapanDepartment of Medicine, Hino Municipal Hospital, 4-3-1 Tamadaira, Hino-shi, Tokyo 191-0062, JapanGiant cell carcinoma, a rare variant of nonsmall cell lung carcinoma (NSCLC), is characterized by aggressive progression and poor response to conventional chemotherapy. This report is the first to describe a patient with NSCLC and giant cell features who was successfully treated with pembrolizumab, an antibody targeting programmed death-1 (PD-1). A 69-year-old woman was diagnosed with NSCLC with multiple brain metastases. Histological evaluation of lung biopsy specimens revealed proliferation of pleomorphic giant tumor cells with poor cohesiveness, findings consistent with giant cell carcinoma. Immunostaining showed that a high proportion of the tumor cells were positive for expression of programmed death-ligand 1 (PD-L1). The patient received stereotactic radiotherapy for the brain metastases, followed by administration of pembrolizumab. Treatment with pembrolizumab resulted in the rapid regression of the primary lung nodule, with the progression-free period maintained for at least four treatment cycles. Immunotherapy targeting PD-1/PD-L1 may be an option for patients with PD-L1-positive NSCLC with giant cell features.http://dx.doi.org/10.1155/2018/5863015 |
| spellingShingle | Shingo Nakayama Mamoru Sasaki Shojiroh Morinaga Naoto Minematsu Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab Case Reports in Oncological Medicine |
| title | Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab |
| title_full | Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab |
| title_fullStr | Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab |
| title_full_unstemmed | Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab |
| title_short | Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab |
| title_sort | nonsmall cell lung carcinoma with giant cell features expressing programmed death ligand 1 a report of a patient successfully treated with pembrolizumab |
| url | http://dx.doi.org/10.1155/2018/5863015 |
| work_keys_str_mv | AT shingonakayama nonsmallcelllungcarcinomawithgiantcellfeaturesexpressingprogrammeddeathligand1areportofapatientsuccessfullytreatedwithpembrolizumab AT mamorusasaki nonsmallcelllungcarcinomawithgiantcellfeaturesexpressingprogrammeddeathligand1areportofapatientsuccessfullytreatedwithpembrolizumab AT shojirohmorinaga nonsmallcelllungcarcinomawithgiantcellfeaturesexpressingprogrammeddeathligand1areportofapatientsuccessfullytreatedwithpembrolizumab AT naotominematsu nonsmallcelllungcarcinomawithgiantcellfeaturesexpressingprogrammeddeathligand1areportofapatientsuccessfullytreatedwithpembrolizumab |